Novel considerations on EGFR-based therapy as a contributor to cancer cell death in NSCLC

Novel considerations on EGFR-based therapy as a contributor to cancer cell death in NSCLC

Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) represented by gefitinib and erlotinib are widely used in treating non-small cell lung cancer (NSCLC). However, acquired resistance to EGFR-TKI treatment remains a clinical challenge. In recent years, emerging research investi...

Full description

Bibliographic Details
Main Authors: Weiwei Peng, Chengyun Yao, Qin Pan, Zhi Zhang, Jinjun Ye, Bo Shen, Guoren Zhou, Ying Fang
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-02-01
Series:Frontiers in Oncology
Subjects:
non-small cell lung cancer (NSCLC)
non-coding RNAs
epidermal growth factor receptor (EGFR)
cell death
combined treatment
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2023.1120278/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2023.1120278/full

Similar Items